You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer

Baumgart, Juliane MD, PhD1,2; Nilsson, Kerstin MD, PhD1,3; Evers, Anneli Stavreus PhD4; Kallak, Theodora Kunovac MSc4; Poromaa, Inger Sundström MD, PhD4

Menopause:
doi: 10.1097/GME.0b013e31826560da
Original Articles
Editorial
Abstract

Objective: The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors.

Methods: A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire.

Results: In all, 42.4% of aromatase inhibitor–treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitor–treated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns.

Conclusions: Our findings suggest that sexual dysfunction in aromatase inhibitor–treated women is a greatly underestimated problem.

Author Information

From the 1Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro, Sweden; Schools of 2School of Health and Medical Sciences, Örebro University, Sweden and3School of Medicine, Örebro University, Örebro, Sweden; and 4Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden.

Received April 1, 2012; revised and accepted June 19, 2012.

Funding/support: Funding for this project was provided by the Uppsala-Örebro Regional Research Council, the Swedish Cancer Society (grant CAN 2009/773), the Swedish Research Council (grant VR 621-2008-3562), Lions Clubs International, and the Percy Falk Foundation.

Financial disclosure/conflicts of interest: I. Sundström Poromaa occasionally serves on advisory boards or speaks at scientific meetings for MSD, Bayer Health Care, and Lundbeck A/S. The other authors report no conflict of interest. The authors are solely responsible for the content and writing of this article.

Address correspondence to: Juliane Baumgart, MD, PhD, Department of Obstetrics and Gynecology, Örebro University Hospital, S-701 85 Örebro, Sweden. E-mail: juliane.baumgart@orebroll.se

© 2013 by The North American Menopause Society.